Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation. - Wikidata - thesis-toulmin - TriplyDB

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

http://www.wikidata.org/entity/Q37376167

about

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.How low can you go? Pushing the limits of low-input ChIP-seq.Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

P2860

Q38975294-5DBDED46-F2CA-4F83-BFED-7251963C3F54 Q47583391-064BE217-FED7-4D6F-8F6E-9966480BC630 Q48112811-84C784D4-C9E3-4B05-AA07-0E66A43F7637

P2860

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

http://www.wikidata.org/entity/Q37376167

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Neoadjuvant tamoxifen synchron ...... to outcome and proliferation.

@en

Neoadjuvant tamoxifen synchron ...... to outcome and proliferation.

@nl

type

label

Neoadjuvant tamoxifen synchron ...... to outcome and proliferation.

@en

Neoadjuvant tamoxifen synchron ...... to outcome and proliferation.

@nl

prefLabel

Neoadjuvant tamoxifen synchron ...... to outcome and proliferation.

@en

Neoadjuvant tamoxifen synchron ...... to outcome and proliferation.

@nl

P1433

Q37376167-486A1C2A-CBB5-4224-871B-313D3ED6B9A1

P1476

Q37376167-8D8890BD-5F3C-42D5-A642-D1F3E05ABBEF

P2093

Q37376167-298C5B60-E9ED-423B-B665-909E2CA1FC0C

Q37376167-29E68008-EA12-49C3-AF7A-F840B4EEE9D3

Q37376167-4955E657-D47B-4430-BA3F-1B740835E67C

Q37376167-4FCCBFBF-BEE0-4362-BDCB-A41584ECE623

Q37376167-68A02E15-6F1D-41E4-9583-2A883D4C2F74

Q37376167-6BF45AE7-A794-4D93-A4A0-1062962C8275

Q37376167-6C0568CC-EEE4-4D28-AEFC-006C0245D8D1

Q37376167-73E957BB-8322-4E99-B33E-C2CFE77B31EB

Q37376167-8682D540-27CB-4BC0-A920-88B96955C841

Q37376167-917A2134-A2E5-4B0A-8454-20243E864970

P2860

Q37376167-0BCB9438-56FD-4949-93A1-D08EC319FB08

Q37376167-15EA533A-9042-48B2-96A9-C0136E62A0A8

Q37376167-1DCC8150-284B-4146-9309-6EC06B077C41

Q37376167-21E3772E-AB46-43F8-856C-5305372C920D

Q37376167-258AE15F-8EB5-434B-897E-CFF5EBFB0743

Q37376167-2634EBF7-B3C9-4101-869E-E3AA25D30A4B

Q37376167-2BFB5F1E-909F-44B0-8C20-8BE40238FA62

Q37376167-2E76648D-764A-4D59-A5F3-BF68841333F3

Q37376167-2F01344E-798A-46B9-ADEB-C27F7CB25A02

Q37376167-33CB0626-0744-40D1-828E-43229FE93621

P304

Q37376167-6849ADEF-9F0D-4BCB-9B7C-A4858BC505C9

P31

Q37376167-3170C2C9-48D9-46F6-9B93-83DEAF07F2DA

P356

Q37376167-9E42ED05-2F67-4900-94A3-D4BDADF8E677

P407

Q37376167-9BA5C962-303E-478D-87E0-60CFE2EC5EFE

P433

Q37376167-FADE2B7E-5554-4F49-9138-E15C0B7FA916

P478

Q37376167-6B3FA6B1-E62A-4384-AB81-80915A7AB52F

P50

Q37376167-2185579F-F04B-4ED2-88F1-0AD960A6392F

Q37376167-84EB87B4-9DDE-4195-BFBD-DCD327E12163

P577

Q37376167-9A6792D6-132C-4057-81A7-F3AB52808251

P5875

Q37376167-84908E39-FF62-41C5-9FD7-023982625D08

P698

Q37376167-86E8DA58-4A82-4058-B100-554E88D4D99F

P932

Q37376167-D3FE82F5-2810-4CAB-8472-1AC9638157CA

P356

ONCOTARGET.8983

P1433

P1476

Neoadjuvant tamoxifen synchron ...... d to outcome and proliferation

@en

P2093

Annelot van Rossum

http://www.w3.org/2001/XMLSchema#string

Daniel Peeper

http://www.w3.org/2001/XMLSchema#string

Ekaterina Nevedomskaya

http://www.w3.org/2001/XMLSchema#string

Inès Beumer

http://www.w3.org/2001/XMLSchema#string

Iris M Simon

http://www.w3.org/2001/XMLSchema#string

Jelle Wesseling

http://www.w3.org/2001/XMLSchema#string

Justine Peeters

http://www.w3.org/2001/XMLSchema#string

Lodewyk Wessels

http://www.w3.org/2001/XMLSchema#string

Marjolein Droog

http://www.w3.org/2001/XMLSchema#string

Oscar Krijgsman

http://www.w3.org/2001/XMLSchema#string

P2860

Model-based analysis of ChIP-Seq (MACS)

Cistrome: an integrative platform for transcriptional regulation studies

Enhancer activation requires trans-recruitment of a mega transcription factor complex

From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription

Progesterone receptor modulates ERα action in breast cancer.

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

P304

33901-33918

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8983

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

301736865

http://www.w3.org/2001/XMLSchema#string

P698

27129152

http://www.w3.org/2001/XMLSchema#string

P932

5085127

http://www.w3.org/2001/XMLSchema#string